Xcenda on Tuesday, May 21, announced the acquisition of Dymaxium as it looks to streamline the exchange of value information between drug manufacturers and payers.
As part of the deal, Xcenda will acquire Dymaxium’s FormularyDecisions.com platform which was launched to provide payers “efficient access to clinical evidence and economic product information critical to their assessment of products for formulary evaluations,” according to a press release.
“We are constantly searching for innovative offerings that make this exchange of information between pharma and payers simpler and more efficient,” Xcenda President Kristine Flemister said in a statement. “We are thrilled to make this a reality through this acquisition with Dymaxium’s FormularyDecisions.com and the AMCP eDossier system.”
Dymaxium Managing Director Allen Lising says the venture expands on the organization’s “vision to make early and ongoing exchange of credible product value information between payers and manufacturers a reality.”
To read the full press release, click here.